Most Effective Treatment for Bipolar Disorder

Psychotic conditions, such as schizophrenia and bipolar disorder, can be difficult to manage without proper treatment and support. Unfortunately, these conditions can often appear during adolescence and can be misunderstood and stigmatized, making it challenging for adolescents to seek help. If you or someone you know is struggling with their mental health, it’s important to understand the symptoms of psychosis and the treatment options that are available to you.

In this blog, we will explore common misconceptions surrounding psychotic disorders, symptoms of these conditions, coping strategies, the importance of medication and therapy, and how to find an adolescent mental health clinic near you.

‍

Understanding the Symptoms of Psychotic Disorders

Psychotic conditions in adolescents can manifest in a variety of ways. Symptoms may include hallucinations, delusions, disorganized speech or behavior, and difficulty with thinking or concentration. Some adolescents with psychotic disorders may also experience mood disturbances, such as depression or mania. These symptoms can be very distressing and can interfere with daily life and the ability to care for oneself. This highlights the importance of accessing care for psychosis as early as possible.

‍

Coping Strategies for Living with Psychotic Disorders

Living with psychosis can be challenging, but there are many coping strategies that can help. One of the most important things is to maintain a routine and a sense of structure in one’s daily life. This can include things like setting a regular sleep schedule, eating nutritious meals, and engaging in meaningful activities. It’s also important to have a support network of family, friends, or healthcare professionals who can offer emotional support and practical assistance, when needed.

‍

The Importance of Medication and Therapy in Managing Psychotic Disorders

Medication and therapy are essential components of managing adolescent psychotic disorders. Medications can help alleviate symptoms and improve overall quality of life, but finding the right medication and dosage can take time and adjustments may be required before landing on the right medication regimen. Therapy, such as cognitive behavioral therapy or psychoeducation, can help adolescents learn coping strategies, improve social skills, and manage symptoms. This highlights the importance of finding a mental health clinic that provides specialized treatment for adolescent mental health.

‍

Misconceptions and Stigmas Surrounding Psychotic Disorders

Adolescents with psychotic disorders often face discrimination, fear, and prejudice due to common misconceptions surrounding these conditions. One of the most prevalent stigmas is the belief that people with psychotic conditions are violent or dangerous. In fact, research has shown that when treated, adolescents with psychotic disorders are more likely to be victims of violence than perpetrators. Other misconceptions include the idea that adolescents with these conditions are lazy or lack motivation, or that they are unable to function in society. These misunderstandings are untrue and many people with psychosis recover and go on to live rich and fulfilling lives.

‍

Finding an Adolescent Mental Health Clinic Near You

Finding an adolescent mental health clinic near you is crucial for adolescents living with psychotic conditions. A clinic like Amae Health that specializes in psychosis, schizophrenia and bipolar disorder can provide tailored treatment and support to help manage symptoms of these conditions and improve overall quality of life. It’s important to connect with others who understand what you’re going through and can offer empathy, advice, and encouragement.

In summary, if you or someone you know is in need of care, it’s important to take action. At Amae Health, we’re ready to help and can help you get back on track with life. We can be reached by email at hello@amaehealth.com. By understanding the symptoms and finding an adolescent mental health clinic that provides specialized treatment, individuals with psychotic conditions can lead fulfilling and meaningful lives.

‍

Spravato success rate figures are easy to find and hard to compare. In the trial that supported its FDA approval, 69.3% of people who finished 4 weeks of Spravato with a new antidepressant had responded, and 52.5% were in remission. A study of routine care in Italy found 64.2% response and 40.6% remission at 3 months. The numbers answer slightly different questions, but they agree on the essentials: Spravato helps many people with treatment-resistant depression, response is more common than remission, and no single percentage tells the whole story.

Spravato also leaves a real share of people without enough relief.

Spravato is the brand name for esketamine, a nasal spray FDA-approved for treatment-resistant depression: depression that hasn't responded adequately to at least two antidepressants, each given at a proper dose for long enough.

What "Success" Means: Response vs. Remission

Nearly every Spravato statistic comes from one yardstick, the Montgomery-Åsberg Depression Rating Scale (MADRS). It's a 10-item interview a clinician scores from 0 to 60, where higher means more severe, and people entering Spravato's main approval trial averaged about 37. Two thresholds turn that score into a success rate:

• Response means the MADRS score has fallen by at least half from where it started.
• Remission means the score has dropped to 12 or lower, the cutoff the Spravato trials used.

The distance between the two is wide. Someone who starts at 38 and falls to 19 counts as a responder and may still have symptoms that get in the way of work, sleep, or relationships. Remission is the fuller recovery and the harder bar, so every remission figure below sits under its response figure.

Spravato's Success Rate in the Trial Behind Its Approval

The short-term trial that supported FDA approval was TRANSFORM-2, published in The American Journal of Psychiatry in 2019. Researchers at 39 outpatient centers enrolled adults with moderate to severe depression who hadn't responded to at least two antidepressants in their current episode. Everyone switched to a new oral antidepressant. One group also received Spravato, 56 or 84 mg twice a week, and the other a placebo spray. Of 227 people randomized, 197 finished the 4-week double-blind phase, and MADRS scores in the Spravato group fell 4 points more, on average.

The European Medicines Agency's review of the trial data translates that into response and remission:

Look first at the comparison group: more than half of the people who started a new antidepressant with a placebo spray also responded. The trial's finding is the gap. Among people who completed 4 weeks, adding Spravato meant about 17 more responders and 21 more remitters in every 100.

The counting method matters too, and it explains much of the inconsistency online. Figures near 69% count only people who finished. Figures near 63% for response, or 48% for remission, carry forward the last score of everyone who stopped early.

Real-World Success Rates

Trials select their patients carefully and follow them for weeks. Routine care is messier, which is what makes REAL-ESK useful. That 2022 study, published in the Journal of Affective Disorders, reviewed the medical records of 116 people with treatment-resistant depression treated with Spravato at several Italian mental health services, with assessments at 1 and 3 months.

By 3 months, 64.2% had responded and 40.6% were in remission, and both rates had climbed sharply between the first month and the third. The authors called that later response one of the study's novel findings. They also found no difference in effectiveness between people with other psychiatric conditions and people without them.

Lining those numbers up against TRANSFORM-2 doesn't work cleanly. REAL-ESK had no placebo or comparison group, everyone knew they were receiving Spravato, ratings weren't checked for consistency across centers, and 3 months is a different finish line from 4 weeks. It's encouraging evidence from everyday practice, not a controlled measure of effect.

Who Spravato Is Approved and Studied For

Spravato has two FDA-approved uses, built on separate trials, according to its prescribing information:

• Treatment-resistant depression in adults, on its own or with an oral antidepressant. The original 2019 approval required an oral antidepressant alongside it; standalone use was added in January 2025.
• Depression with acute suicidal thoughts or behavior, in adults with major depressive disorder, given alongside an oral antidepressant to treat the depressive symptoms.

The second use came from trials of a different group: adults with moderate to severe depression and active suicidal thoughts with intent, all of whom began with an inpatient psychiatric stay and standard care, and 63% of whom had attempted suicide before. Those results shouldn't be mixed with the treatment-resistant depression results.

The label is explicit about one boundary. Spravato hasn't been shown to prevent suicide or to reduce suicidal thoughts or behavior, and it doesn't replace hospitalization when that's needed, even if someone feels better after the first dose. It isn't approved for children. If suicidal thoughts are part of what you're living with right now, care for suicidal thoughts comes first, and 988 answers calls and texts at any hour.

How Fast Results Typically Appear

Spravato's reputation for speed comes from the first day. In TRANSFORM-2, most of the difference from placebo was already visible at 24 hours, the label reports; both groups kept improving through day 28, and the gap held steady rather than widening. The monotherapy trial behind the 2025 approval showed an effect at about 24 hours that lasted through day 28. In the suicidal-thoughts trials, the difference appeared as early as 4 hours.

Early movement isn't the same as response. In TRANSFORM-2, only 7.9% of people on Spravato had a response that began by day 2 and held through day 28, compared with 4.6% on placebo spray, a difference that wasn't statistically significant in the EMA review. The label calls for judging benefit at the end of the 4-week induction phase, after which sessions drop from twice a week to weekly.

And as REAL-ESK suggests, for some people even 4 weeks is early.

What Affects Individual Success

Research points to a handful of factors linked to outcomes, none of them a forecast for any one person:

• Time on treatment. Benefit is formally assessed after the 4-week induction phase, and in REAL-ESK, many responses and remissions arrived between the first and third month.
• Continuing after a good response. In a maintenance study described in the label, people in stable remission who kept taking Spravato went significantly longer before relapsing than people switched to a placebo spray, and the same held for people in stable response.
• Age. The evidence is weaker in older adults. In a separate short-term trial of adults 65 and older, response at day 28 was 27.0% with Spravato versus 13.3% with placebo spray, and the trial's main measure narrowly missed statistical significance, per the EMA review.
• Other psychiatric conditions. REAL-ESK found people with additional psychiatric diagnoses did as well as people without them.
• With or without an oral antidepressant. Spravato has shown benefit both ways, but no trial in the label compared the two head to head.

Limits and Risks

The same data show where Spravato falls short.

• Many people don't reach remission. Nearly half of the people who completed TRANSFORM-2 on Spravato weren't in remission at day 28, and in REAL-ESK, about six in 10 weren't in remission at 3 months.
• Not every trial was positive. Of the three short-term trials submitted for approval, only TRANSFORM-2 met its main goal. A fixed-dose trial in adults and the trial in older adults both fell short of statistical significance, according to the EMA review.
• It carries a boxed warning for sedation, dissociation, breathing problems (respiratory depression), and misuse or abuse, plus the risk of suicidal thoughts and behaviors that antidepressants carry for children and young adults. Sedation showed up in 48% to 61% of trial participants on Spravato, and dissociation, a sense of detachment that can warp time, space, or surroundings, in 61% to 84%.

Those risks shape how Spravato is given. It's only available through a restricted program called the Spravato REMS. You use the spray yourself under supervision in a certified healthcare setting, your blood pressure is checked before and after, and you're monitored for at least 2 hours before you're cleared to leave. Driving is off-limits until the next day, after a night of restful sleep. People with certain blood vessel problems, including an aneurysm, an abnormal connection between arteries and veins, or past bleeding in the brain, can't take it at all.

Talking to a Psychiatrist About Your Options

A Spravato success rate is a group statistic. It shows that Spravato helps a substantial share of people with treatment-resistant depression and that remission is harder to reach than response. It can't tell you what will happen for you. That depends on your diagnosis, what you've tried and for how long, your medical history, and the rest of your care.

We don't offer Spravato at Amae. Major depressive disorder is among the conditions our clinics specialize in, and when it hasn't eased with medication, our psychiatrists treat it within our integrated care model, which puts psychiatry, medication management, therapy, and primary care on one team. TMS therapy runs at three of our clinics: Los Angeles, Los Altos, and San Mateo. Our comparison of TMS, ketamine, and Spravato and our look at TMS success rates lay out how those options differ. To go over your history with someone who can see all of it, schedule an evaluation with an Amae psychiatrist. Anyone in immediate danger should call 911.

Frequently Asked Questions

What is Spravato's success rate in clinical trials?

In TRANSFORM-2, the short-term trial behind FDA approval, 69.3% of people who completed 4 weeks of Spravato plus a new antidepressant responded and 52.5% reached remission, versus 52.0% and 31.0% with a placebo spray plus a new antidepressant. Counting people who left early, remission was 48.2% versus 30.3%.

Does Spravato work better in real-world use than in trials?

The figures look similar, but they can't be compared directly. REAL-ESK, a study of 116 people treated in routine care in Italy, found 64.2% response and 40.6% remission at 3 months, with no placebo group and a longer follow-up than the 4-week trials.

How fast does Spravato start working?

Average scores often pull ahead of placebo within 24 hours, and in trials of people with suicidal thoughts, within 4 hours. A lasting response that early is uncommon, so benefit is judged after the 4-week induction phase, and some people improve later still.

Does Spravato work for everyone?

No. In TRANSFORM-2, nearly a third of people who completed treatment didn't respond, and nearly half didn't reach remission. Two other short-term trials, including one in adults 65 and older, didn't reach statistical significance on their main measure.

What happens if Spravato doesn't work for me?

A psychiatrist looks at the whole picture again: the diagnosis, whether treatment ran long enough, other medications, and other conditions. Next steps might include a different medication strategy, adding or changing therapy, or another treatment for treatment-resistant depression, such as TMS or ECT.

Is Spravato's success rate different for suicidal depression versus treatment-resistant depression?

Yes, and the two shouldn't be blended. The suicidal-thoughts trials measured average score changes 24 hours after the first dose in hospitalized adults receiving standard care. Spravato lowered depression scores more than placebo, but it didn't improve a rating of suicidality more than placebo, and it hasn't been shown to reduce suicidal thoughts.

Citations

1. Popova V, Daly EJ, Trivedi M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. The American Journal of Psychiatry. 2019;176(6):428-438. https://pubmed.ncbi.nlm.nih.gov/31109201/ (Tier 1)
2. European Medicines Agency. Spravato: EPAR public assessment report (EMA/614876/2019). 2019. https://www.ema.europa.eu/en/documents/assessment-report/spravato-epar-public-assessment-report_en.pdf (Tier 2, regulatory review)
3. Martinotti G, Vita A, Fagiolini A, et al. Real-world experience of esketamine use to manage treatment-resistant depression: a multicentric study on safety and effectiveness (REAL-ESK study). Journal of Affective Disorders. 2022;319:646-654. https://pubmed.ncbi.nlm.nih.gov/36167246/ (Tier 1)
4. U.S. Food and Drug Administration. SPRAVATO (esketamine) nasal spray prescribing information, revised April 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s019lbl.pdf (Tier 2)
5. 988 Suicide and Crisis Lifeline. https://988lifeline.org (Tier 2)

The search for the best outpatient mental health program in Los Angeles usually starts at a hard moment: weekly therapy is not enough, or someone is leaving a hospital and needs a bridge back to normal life, and search results return a wall of near-identical program listings. The programs behind those websites are not interchangeable. They differ in intensity, in the conditions they know deeply, in who leads the care, and in the insurance they take.

‍

Mental health treatment in Los Angeles spans everything from a weekly therapy hour to structured programs that run most of the day, most of the week. This guide explains those levels of care, profiles established providers across the city organized by what each one is actually for, and walks through cost, insurance, and how to choose, so the decision rests on fit rather than on whoever ranks first.

Levels of Outpatient Care in Los Angeles: PHP vs IOP vs Outpatient

Before comparing providers, it helps to know which level of care you are comparing them for. IOP in Los Angeles generally means several structured hours a few days per week, while PHP treatment in Los Angeles runs closer to a full clinical day. SAMHSA defines partial hospitalization as structured ambulatory care delivered more than three hours per day, more than two days per week, the most intensive tier short of an overnight stay (SAMHSA, N-SUMHSS Definitions).

‍

Treat the schedules as typical ranges; exact hours vary by program. The common thread is that every level is outpatient: you sleep at home, and the level of care adjusts as you stabilize. The levels also exist for a practical reason. Insurers authorize care by medical necessity, so a clinical assessment places you at the intensity your symptoms actually require, and treatment steps down as you improve. Moving from PHP to IOP to weekly therapy is the expected arc, not a setback.

Best Outpatient Mental Health Programs in LA

Rather than rank programs against each other, the profiles below are grouped by what each provider is built for: integrated care for severe mental illness, academic medicine, children and teens, affordable therapy, community and crisis services, and the public system. Details were verified from each provider as of 2026; programs and networks change, so verify specifics directly.

Amae Health: Integrated PHP, IOP, and Outpatient Care for Severe Mental Illness (Westwood)

Amae Health's LA clinic, at 11620 Wilshire Boulevard, Suite 520, is a psychiatry-led outpatient clinic designed by UCLA- and VA-trained psychiatrists for adults living with severe and complex conditions: schizophrenia, schizoaffective disorder, bipolar disorder, severe depression, and first-episode psychosis. Care operates in collaboration with NewYork-Presbyterian and is supported by Cedars-Sinai.

‍

What distinguishes the model is the combination of a full level-of-care range with one team. We offer a Partial Hospitalization Program, an Intensive Outpatient Program, and standard outpatient care, so a person can step down in intensity without changing providers. In practice that means the psychiatrist who directed your PHP still knows your history when you reach weekly visits months later, and nothing gets lost in translation. The team brings psychiatrists, therapists delivering integrated CBT and DBT, primary care, peer support specialists, and dietitians under one roof, with TMS therapy available for treatment-resistant depression.

‍

• Levels of care: PHP, IOP, and outpatient
• Ages served: Adults 18 and older
• Insurance: In-network with Aetna, Anthem Blue Cross, Blue Shield of California, Cigna/Evernorth, and Optum; same-day appointments available
• Phone: (310) 601-5099
• Best for: Adults with serious or complex mental illness who need a full range of outpatient intensity from a single, psychiatry-led team

UCLA Resnick Neuropsychiatric Hospital: Academic Medical Center Programs (Westwood)

UCLA's Resnick Neuropsychiatric Hospital anchors academic psychiatry in Los Angeles. Its adult partial hospitalization and intensive outpatient programs at 760 Westwood Plaza provide daytime acute care with specialty tracks spanning severe mood disorders, thought disorders, OCD, trauma, dual diagnosis, and postpartum mood disorders, alongside a wide network of outpatient specialty clinics. As with most academic centers, the strengths are subspecialty depth and research access; the tradeoff is that intake can move slower than at private clinics.

‍

• Levels of care: Outpatient specialty clinics, PHP, and IOP
• Ages served: Adults, with separate child and adolescent services
• Best for: People who want university-hospital subspecialty expertise and can wait for an intake

Children's Hospital Los Angeles: Outpatient Psychiatry for Kids and Teens (Mid-Wilshire)

The Behavioral Health Institute at Children's Hospital Los Angeles provides outpatient psychiatry built entirely around children and adolescents, a population most adult programs are not designed for. Board-certified child and adolescent psychiatrists treat depression, anxiety, ADHD, bipolar disorder, autism spectrum disorders, trauma, and eating disorders through therapy, family work, and medication management at its 3250 Wilshire Boulevard clinic.

‍

• Levels of care: Outpatient psychiatry and therapy
• Ages served: Children and adolescents
• Best for: Families seeking pediatric-specialized psychiatric care for a child or teen

Wright Institute Los Angeles: Affordable, Open-Ended Therapy (West LA)

Wright Institute Los Angeles (WILA) is a nonprofit psychotherapy and training clinic on West Olympic Boulevard that offers individual, couples, family, and group therapy on a sliding scale. Because it receives no governmental funding tied to session caps, therapy can continue as long as a client needs it rather than ending at an arbitrary limit. This is talk therapy rather than a structured day program, which is exactly its role in the landscape.

‍

• Levels of care: Standard outpatient therapy
• Ages served: Adults, couples, and families
• Cost: Sliding-scale fees based on income
• Best for: People who need affordable, long-term weekly therapy rather than intensive programming

Didi Hirsch Mental Health Services: Community and Crisis Care (Multiple Locations)

Didi Hirsch has provided community-based mental health care across Los Angeles since 1942 and is nationally known for its Suicide Prevention Center. Its programs span outpatient mental health services, substance use treatment, crisis intervention, and support for families affected by trauma and loss, serving communities that private-pay clinics often miss.

‍

• Levels of care: Community outpatient and crisis services
• Ages served: Children through adults, by program
• Best for: Community-based care, crisis support, and families navigating suicide loss or trauma

Los Angeles County Department of Mental Health: The Public Safety Net (Countywide)

LACDMH is the largest county mental health department in the United States, serving residents with serious mental illness through directly operated and contracted clinics across the county. Services include assessment, therapy, medication, case management, and crisis response, with access built around Medi-Cal. The 24/7 ACCESS line at 1-800-854-7771 is the entry point.

‍

• Levels of care: Outpatient, case management, and crisis services
• Ages served: All ages
• Insurance: Serves Medi-Cal members and uninsured residents
• Best for: County residents who need public, low-cost, or Medi-Cal-covered care

Conditions Treated in LA Outpatient Programs

Most outpatient programs treat a broad range of conditions; fewer are built for complex presentations. When comparing, check depth in your specific diagnosis:

‍

• Schizophrenia and schizoaffective disorder: these call for psychiatry-led programs with experience in psychosis, not therapy-only settings
• Bipolar disorder: best managed where psychiatry and therapy are integrated in one plan
• Severe or treatment-resistant depression: ask whether the program offers interventional options such as TMS alongside medication and therapy
• First-episode psychosis: early, structured intervention through PHP or IOP improves the long-term course
• Anxiety disorders, PTSD, and trauma: widely treated; look for clinicians trained in trauma-focused modalities
• Personality disorders and emotional dysregulation: DBT-focused programming matters here; CBT and DBT are among the best-studied psychotherapies for these conditions (NIMH, Psychotherapies)
• Co-occurring mental health and substance use: integrated dual-diagnosis treatment beats parallel, disconnected care

What to Look for in an LA Outpatient Program

Seven factors separate the marketing from the medicine when comparing mental health treatment in Los Angeles:

‍

• Level of care offered. PHP, IOP, or both, and whether the program supports stepping down between levels without a referral elsewhere.
• Specialization. Severe and complex psychiatric conditions, general mental health, and substance-use-focused programs are different competencies.
• Psychiatry-led vs. therapy-only. Ask whether psychiatrists direct care and whether medication management happens on-site or gets referred out.
• Treatment modalities. Look for evidence-based approaches: CBT, DBT, ACT, and trauma-informed care.
• Insurance accepted. Several private West LA programs take commercial insurance only; public and county options cover Medi-Cal. Confirm your plan before enrolling.
• Schedule. Daytime PHP versus evening or hybrid IOP; in-person versus virtual options.
• Location and access. Many programs cluster in West LA and Westwood; a daily commute across the city adds real strain for a program requiring frequent attendance.

How to Choose the Right Level of Care

The choice between PHP, IOP, and standard outpatient is a clinical one, and you do not have to make it alone. A structured assessment, which most programs run on the first call along with insurance verification, determines the right starting intensity. As a rule of thumb: PHP fits severe symptoms or the step-down from a hospital stay; IOP fits someone who needs real structure while keeping work, school, or caregiving intact; standard outpatient fits stable symptoms and maintenance.

‍

Expect movement between levels. Many people begin in PHP and step down to IOP as they stabilize, which is why a provider offering both levels under one roof saves a disruptive mid-treatment handoff.

‍

A few questions to ask on that first call:

‍

• Which levels of care do you offer, and can I step down within your program?
• Is care psychiatrist-led, and is medication management handled on-site?
• Do you have specific experience with my diagnosis?
• Are you in-network with my plan, and is prior authorization needed?
• How soon is the first available intake?

‍

Before committing anywhere, confirm the program treats your specific diagnosis and takes your insurance. If you want help thinking it through, contact Amae Health for an evaluation. To cast a wider net, SAMHSA's national locator at FindTreatment.gov searches programs by location, condition, and payment type, and the Psychology Today directory covers individual therapists for standard outpatient care.

How Much Does Outpatient Treatment Cost in LA?

With insurance: most commercial plans cover IOP and PHP when medically necessary, and federal parity law requires mental health benefits to be no more restrictive than medical ones (CMS, MHPAEA). Prior authorization is common, and in-network copays vary by plan. One practical LA-specific caution: a number of private Westside programs accept commercial insurance only, while county and community providers accept Medi-Cal, so coverage type meaningfully narrows the list.

‍

Without insurance: IOP and PHP are typically billed per day or per program, and costs vary widely by provider and level of care. Ask directly about private-pay rates, and about sliding-scale options; nonprofits like WILA exist precisely to make ongoing therapy affordable, and LACDMH serves uninsured residents.

‍

Out-of-network: if the program you want is not in your network, ask for a superbill, an itemized receipt you submit to your insurer for partial reimbursement. Reimbursement percentages vary by plan, so ask your insurer for the out-of-network mental health rate before enrolling rather than after.

Where to Start

If the options still feel unclear, return to the three questions that matter most: what level of care does a clinical assessment recommend, which programs have real depth in your diagnosis, and who takes your insurance. Answer those in order and the list narrows itself. For adults living with serious or complex mental illness in Los Angeles, that shortlist often ends at care that is psychiatry-led and integrated; you can see how we build that model across our full range of treatments, or call (310) 601-5099 to talk it through with our Westwood team.

Frequently Asked Questions

What is the best outpatient mental health program in Los Angeles? The strongest program for you is the one matched to your diagnosis, required level of care, and insurance, not a citywide ranking. For severe and complex conditions, Amae Health in Westwood offers psychiatry-led PHP, IOP, and outpatient care in one team; UCLA serves academic subspecialty needs; CHLA covers children; and county programs cover Medi-Cal.

‍

What is the difference between IOP and PHP in Los Angeles? Intensity. PHP runs about six hours a day, five days a week, for severe symptoms or a step-down from inpatient care. IOP runs about three hours a day, three to five days a week, for people who need structure while continuing daily life.

‍

Does insurance cover outpatient mental health treatment in LA? Most commercial plans cover IOP and PHP when medically necessary, usually with prior authorization. Medicare and Medicaid acceptance varies sharply by program; several private Westside programs are commercial-only, while county providers accept Medi-Cal. Verify before enrolling.

‍

Where are most outpatient programs in LA located? They cluster in West LA and Westwood, near Century City, Santa Monica, Brentwood, and Beverly Hills. Amae Health sits in Westwood at 11620 Wilshire Boulevard. Factor the daily commute into the decision, since PHP and IOP require frequent attendance.

‍

Can I work or go to school while in an outpatient program? Usually, yes, in IOP, which is built around daily responsibilities, and some programs run evening or virtual tracks. PHP occupies most of the day, so people often use medical or family leave during it.

‍

What conditions do LA outpatient programs treat? Depression, anxiety, bipolar disorder, PTSD, personality disorders, and co-occurring substance use are widely treated. A smaller set of programs, including Amae Health, specializes in severe conditions such as schizophrenia, schizoaffective disorder, and first-episode psychosis. If you are in crisis right now, call or text the 988 Suicide and Crisis Lifeline at 988.

‍

Citations

1. SAMHSA, National Substance Use and Mental Health Services Survey (N-SUMHSS) Definitions: "Partial hospitalization/day treatment." info.nsumhss.samhsa.gov/definitions.htm. Tier 2 (U.S. government).
2. National Institute of Mental Health, "Psychotherapies." nimh.nih.gov/health/topics/psychotherapies. Tier 2 (U.S. government).
3. Centers for Medicare & Medicaid Services, "The Mental Health Parity and Addiction Equity Act (MHPAEA)." cms.gov. Tier 2 (U.S. government).

‍